Paperonium

Antibiotics · BMC Med · 2025

Flomoxef: 0 gut infections. Cefmetazole: 4. The paper says “significantly less common”; chance easily explains it.

1 in 100every time1 in 20the usual barabout1 in 33The paper’s textevery timeIts table: 0 of 673 vs 4 of 4,796
1 in 100every time1 in 20the usual barabout1 in 33The paper’s textevery timeIts table:0 of 673 vs 4 of 4,796

With equally safe drugs, how often chance gives a split at least this unexpected

The paper says

For hospital patients with urinary infections, the paper’s summary says gut infections were significantly rarer on the antibiotic flomoxef than on cefmetazole. Its results section gives p = 0.03: chance alone would split the cases at least this unexpectedly about 1 time in 33.

Its own data show

The paper’s own table of side effects disagrees: 0 cases among 673 flomoxef patients, 4 among 4,796 on cefmetazole, p = 1. Flomoxef patients were about 1 in 8 of everyone, so equally safe drugs would give them about 1 in 8 of the 4 cases: half a case. Nothing in the paper explains 0.03.

A p-value is how often chance alone, with equally safe drugs, gives a split at least this unexpected. Half a case is impossible, so 0 versus 4 is the least unexpected split possible: p = 1, which means every time. The summary calls this a safety advantage of flomoxef; its other one, less kidney failure, holds up.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data · BMC Med (2025) · doi:10.1186/s12916-025-04130-x